medigraphic.com
ISSN 0035-0052 (Print)

2017, Number 6

Next >>

Rev Mex Pediatr 2017; 84 (6)

Survival in children with leukemia; a great challenge for our contemporary society

Rendón-Macías ME, Reyes-Zepeda NC

Language: Spanish
References: 24
Page: 213-215
PDF size: 148.88 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Starý J, Hrušák O. Recent advances in the management of pediatric acute lymphoblastic leukemia. F1000Research. 2016; 5: 2635.

  2. Pérez-Saldivar ML, Fajardo-Gutiérrez A, Bernáldez-Ríos R, Martínez-Avalos A, Medina-Sanson A, Espinosa-Hernández L et al. Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology. BMC Cancer. 2011; 11: 355.

  3. Wang L, Gomez SL, Yasui Y. Racial and ethnic differences in socioeconomic position and risk of childhood acute lymphoblastic leukemia. Am J Epidemiol. 2017; 185(12): 1263-1271.

  4. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012; 30(14): 1663-1669.

  5. Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89,828 children from 198 registries in 53 countries. Lancet Haematol. 2017; 4(5): e202-e217. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2352302617300522

  6. Yifru S, Muluye D. Childhood cancer in Gondar University Hospital, Northwest Ethiopia. BMC Res Notes. 2015; 8: 474. Available from: http://www.biomedcentral.com/1756-0500/8/474

  7. Jabeen K, Ashraf MS, Iftikhar S, Belgaumi AF. The impact of socioeconomic factors on the outcome of childhood acute lymphoblastic leukemia (ALL) treatment in a low/middle income country (LMIC). J Pediatr Hematol Oncol. 2016; 38(8): 587-596.

  8. Pui C-H, Pei D, Pappo AS, Howard SC, Cheng C, Sandlund JT et al. Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children’s Research Hospital, 1992 Through 2007. J Clin Oncol. 2012; 30(16): 2005-2012.

  9. Jakab Z, Juhasz A, Nagy C, Schuler D, Garami M. Trends and territorial inequalities of incidence and survival of childhood leukaemia and their relations to socioeconomic status in Hungary, 1971-2015. Eur J Cancer Prev. 2017; 26: S183-190.

  10. Jiménez-Hernández E, Jaimes-Reyes EZ, Arellano-Galindo J, García-Jiménez X, Tiznado-García HM, Dueñas-González MT et al. Survival of mexican children with acute lymphoblastic leukaemia under treatment with the protocol from the dana-farber cancer institute 00-01. Bio Med Res Int. 2015; 2015: 576950.

  11. Carroll WL, Hunger SP. Therapies on the horizon for childhood acute lymphoblastic leukemia. Curr Opin Pediatr. 2016; 28(1):12-18.

  12. Navarrete M, Rossi E, Brivio E, Carrillo JM, Bonilla M, Vasquez R et al. Treatment of childhood acute lymphoblastic leukemia in central America: a lower-middle income countries experience. Pediatr Blood Cancer. 2014; 61(5): 803-809.

  13. Martín-Trejo JA, Núñez-Enríquez JC, Fajardo-Gutiérrez A, Medina-Sansón A, Flores-Lujano J, Jiménez-Hernández E et al. Early mortality in children with acute lymphoblastic leukemia in a developing country: the role of malnutrition at diagnosis. A multicenter cohort MIGICCL study. Leuk Lymphoma. 2017; 58(4): 898-908.

  14. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood. 2006; 109(3): 926-935.

  15. Hunger SP. Integrated risk stratification using minimal residual disease and sentinel genetic alterations in pediatric acute lymphoblastic leukemia. J Clin Oncol 2017; JCO2017760504.

  16. Huynh V, Laetsch TW, Schore RJ, Gaynon P, O’Brien MM. Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing. Pediatr Hematol Oncol. 2017; 30: 1-14.

  17. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16): 1507-1517.

  18. Afzal S, Ethier MC, Dupuis LL, Tang L, Punnett AS, Richardson SE et al. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J. 2009; 28(12): 1064-1068.

  19. Inaba H, Pei D, Wolf J, Hayden RT, Go M, Varechtchouk O et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Ann Oncol. 2017; 28(2): 386-392.

  20. Keng MK, Sekeres MA. Febrile neutropenia in hematologic malignancies. Curr Hematol Malig Rep. 2013; 8(4): 370-378.

  21. Santiago R, Vairy S, Sinnett D, Krajinovic M, Bittencourt H. Novel therapy for childhood acute lymphoblastic leukemia. Expert Opin Pharmacother. 2017; 18(11): 1081-1099.

  22. Felice MS, Rossi JG, Alonso CN, Rubio P, Gallego MS, Galluzzo ML et al. Second neoplasms in children following a treatment for acute leukemia and/or lymphoma: 29 years of experience in a Single Institution in Argentina. J Pediatr Hematol Oncol. 2017; 39(8): e406-412.

  23. Bonilla M, Moreno N, Marina N, deReyes G, Shurtleff SA, Downing JR et al. Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol. 2000; 22(6): 495-501.

  24. Villasís-Keever MA, Rendón-Macías ME, Escamilla-Núñez A. Estándares para el otorgamiento óptimo de los cuidados que requieren los pacientes pediátricos con leucemia linfoblástica aguda y linfoma de Hodgkin. Bol Med Hosp Infant Mex. 2012; 69(3): 164-174.




2020     |     www.medigraphic.com